PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010 2011 2012 2013
This activity will support the continuation of ART for approximately 2744 South African National Defense Force (SANDF) personnel and family members (as of June 2011) that were previously receiving ARVs via a collaborative clinical trial with the SANDF, HHS/NIH/NIAID, and US DoD. By the end of FY12 we anticipate that the number of HIV+ patients who will be on ART will exceed 2,900 patients as they are identified from a natural history cohort. This PEPFAR funding will ensure continued ARV therapy for these individuals as they are transitioned from the clinical trial to HIV treatment and care still provided through Phidisa clinics and service delivery personnel. This is a very high priority for the SANDF and the South African Military Health Service (SAMHS) and all ART will be prescribed and managed (which will include lab testing and patient monitoring) according to SAG national guidelines. Patient monitoring will be done by dedicated personnel at Phidisa clinics. The labs monitoring tests done in accordance with guidelines will performed at the clinical sites in the same manner for the currently enrolled Phidisa patients. This is done through the current mechanism set by NIAID. PEPFAR funds allocated under this activity will be used by NIAID to procure and distribute ARV drugs to the 6 existing SAMHS clinical sites and for lab monitoring tests to continue coverage for these patients.Background: Project Phidisa initiated Protocol II, a randomized clinical trial, was started in January 2004 at the request of the SANDF, with the support of the US Ambassador to South Africa, and the US DoD. It is the aim of this PEPFAR activity to maintain continuity of the ARV drug supply chain, which has been well integrated with the military clinical sites.
Activities will be focused on procurement, accountability and storage measures. These drugs include: Lopinavir/Ritonavir, Saquinavir, Truvada, Emtricitabine/tenofovir/efavirenz , Atazanavir, and other ART drugs needed to continue therapy for these patients. Phidisa Pharmacist is to be accountable and responsible for acquiring, storing, dispensing and monitoring of Project Phidisa antiretrovirals (ARVs). Since the Project Phidisa began patient enrollment in 2003, there are a number of patients who had failed first line or second line antiretroviral therapy. In these cases, patients have been put on salvage ARVs that are currently not available in the SAMHS procurement supply chain management system. The US NIH-NIAID through an existing contract mechanism will assist with the procurement of these drugs. Since the NIAID contractor has been used in the ARV procurement since the beginning of Project PHIDISA, a fully-functional, effective, existing infrastructure and logistics strategy has already been in place.
The activiites will include clinicians and other personnel, training of personnel, clinical monitoring, related laboratory services, and treatment and patient adherence activities.Training activities will include intermittent in-service training, mentorship to address clinical care and delivery of the HIV infected patients. Personnel will be dedicated to support treatment and monitoring of these patients. All Phidisa sites will continue efforts to improve efficiencies to allow for continued expansion of services and improved delivery of care and treatment. Efforts to retain patients iniated on antiretrovirals (ARV) and adherence modalities that is currently performed will continue at the Phidisa sites. Outcomes of these activities will be monitored periodically to include incorporating suggested performance improvement strategies.
The primary activities and strategies will be aimed at building the capacity of health care providers and facilities to treat children that are being treated at Phidisa sites. This includes training clinicians and other providers, clinical and laboratory monitoring of children on treatment. There are a limited number of pediatric patients as most are treated at SAMHS rollout sites. As these rollout sites expand, activiites will be made to faciliate transitioning of these patients.
